Aim To evaluate the impact of severe hypoglycaemia on NHS resources and overall glycaemic control in adults with Type 1 diabetes.
Introduction
Persistent hyperglycaemia in Type 1 diabetes is associated with microvascular complications and an increased risk of cardiovascular disease [1] . The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive glycaemic control significantly reduced the incidence of microvascular and cardiovascular disease and slowed progression of microvascular complications [1] [2] [3] . However, intensive glycaemic control is associated with an increased risk of severe hypoglycaemia, defined as an event requiring the assistance of another person to treat [1, 4] .
Severe hypoglycaemia is associated with an increased risk of cardiovascular events [5] , a reduction in quality of life, increased fear and anxiety, reduced productivity and ª 2018 Diabetes UK increased healthcare costs [4] . Fear of hypoglycaemia can lead to complex compensatory behaviour resulting in suboptimal glycaemic control and an increased risk of developing chronic complications [4, 6] . Modern Type 1 diabetes management emphasizes structured education, for example through the DAFNE (Dose Adjustment for Normal Eating) programme [7] , to enable people to tailor insulin dosing according to carbohydrate intake and exercise [4, 8] . Despite such developments, severe hypoglycaemia remains a major hazard for people with Type 1 diabetes and is the most common diabetes emergency requiring ambulance service call-out and Accident and Emergency (A&E) attendance [9, 10] . Although studies have reported resource utilization associated with severe hypoglycaemia requiring ambulance attendance [5, 9, [11] [12] [13] [14] , there is limited realworld evidence reporting secondary care resource utilization and clinical intervention specifically associated with episodes of self-reported severe hypoglycaemia in people with Type 1 diabetes.
The objective of this study was to evaluate the impact of self-reported episodes of severe hypoglycaemia on secondary care resource use and diabetes management in people with Type 1 diabetes in a real-world setting, in order to understand current unmet need.
Methods

Study design and setting
We conducted an observational, multicentre, retrospective study of people with Type 1 diabetes in 10 NHS secondary care diabetes centres in England and Wales. Adults (≥ 18 years of age) with Type 1 diabetes currently under the care of participating centres who had been treated with insulin for ≥ 2 years and who had experienced one or more self-reported episode of severe hypoglycaemia in the previous 24 months were eligible for the study.
Participants
Eligible individuals were identified by members of the study team through a review of recent diabetes clinic lists, medical records and local databases and selected in reverse chronological order. Participants gave written informed consent for data collection from medical records according to a protocol approved by the NHS Research Ethics Service (reference 15/ NI/0169). Data were collected between November 2015 and April 2016.
Sample size
As a retrospective descriptive study with a single cohort of participants, no formal power calculation was carried out. A target sample size of 50-80 was chosen to provide a representative sample of people with self-reported episodes of severe hypoglycaemia and provide adequate reliability for the study endpoints.
Variables and outcomes
The primary outcome of the study was a summary of the secondary healthcare resource utilization associated with management of people with Type 1 diabetes self-reporting one or more episodes of severe hypoglycaemia. Healthcare resource utilization included all diabetes clinic consultations, planned and unplanned inpatient admissions, and other points of care in the diabetes pathway, including ambulance call-outs and A&E attendances during a 2-year period prior to data collection (observation period). Secondary outcomes included a summary of the profile of individuals reporting severe hypoglycaemia, their overall glycaemic control and pathway of care. Participant demographic and clinical characteristics (data as recorded closest to the time of data collection) included age, sex, duration of diabetes, BMI, HbA 1c , insulin therapy, comorbidities and concomitant medication. Glycaemic control and pathway of care included all documented episodes of severe hypoglycaemia, HbA 1c measurements and insulin therapy changes recorded during the 2-year observation period. Post-hoc exploratory outcomes included: level of HbA 1c measured closest prior to severe hypoglycaemia; time between episodes of severe hypoglycaemia and hypoglycaemia follow-up consultations; temporal relationship between episodes of severe hypoglycaemia, diabetes clinic consultations and changes to diabetes treatment.
Statistical analyses
Data were analysed with descriptive statistics, using only the available data; denominators are presented for all analyses where data were missing. Quantitative variables are presented as median [interquartile range (IQR) and/or range] or What's new?
• Some 71% of episodes of self-reported severe hypoglycaemia involved ambulance call out.
• Only 13% of all diabetes clinic consultations were documented as hypoglycaemia follow-up and at least 50% of people included in this study had no documented healthcare professional-recommended changes to diabetes treatment.
• The results of our study suggest a lack of a consistent mechanism for reporting by paramedics to primary care and subsequent referral to specialist diabetes services, a lack of a consistent approach to early follow-up by specialist diabetes services, and low levels of healthcare professional-recommended therapy change and ongoing specialist review following self-reported episodes of severe hypoglycaemia.
arithmetic mean (SD). Categorical variables are presented as frequency (%).
Costs associated with hospital resource utilization were calculated using NHS reference costs 2014/2015 [15] .
Subgroup analysis
In order to examine the temporal relationship between episodes of severe hypoglycaemia, diabetes clinic consultations and changes to diabetes treatment, we evaluated a subgroup of 72 severe hypoglycaemic episodes (in 63 people) with 3 months' data available both before (pre-hypoglycaemia) and after (post-hypoglycaemia) the event.
Results
Baseline participant demographic and clinical characteristics
Eighty-five people from 10 hospitals in England and Wales were studied. Demographic and clinical characteristics are shown in Fig. 1 and Table 1 . The mean age at data collection was 57.0 (SD 14.8) years, 59% (n = 50) of participants were men, and the mean duration of diabetes was 33.1 (SD 14.2) years. At least one comorbidity was recorded for 78 (92%) participants [mean of 3.9 comorbidities (SD 2.9) per person]; none had Addison's disease and only one had coeliac disease. The majority were using analogue and/or human sequence insulins, either in a multiple daily injection regimen (MDI) or as a continuous subcutaneous insulin infusion (CSII).
Severe hypoglycaemic events and glycaemic control during the 2-year observation period A total of 140 episodes of severe hypoglycaemia were recorded during the 2-year observation period (median episodes per person = 1, range 1-4); 35 of 85 (41%) participants experienced more than one episode (Fig. 2) . The majority of episodes required the assistance of a paramedic (106 of 140 episodes, 76%). Family members provided assistance for 15% (21 of 140) of episodes.
A mean of 4.3 (SD 1.9) HbA 1c measurements per person (range 1-10) were recorded during the 2-year observation period; 11 of 85 participants (13%) had at least one HbA 1c concentration of ≤ 48 mmol/mol (≤ 6.5%) and 39 of 85 participants (46%) had at least one HbA 1c concentration of ≤ 58 mmol/mol (≤ 7.5%) recorded at some point during the 2-year observation period. For the HbA 1c recorded most closely prior to episodes of severe hypoglycaemia [n = 119 measurements; median time prior to hypoglycaemic episode 104 (range 0-542) days], only 7 of 119 (6%) measurements were < 48 mmol/mol (< 6.5%), and the mean HbA 1c concentration was 70 (SD 19) mmol/mol (8.5%, SD 1.7%) (Fig. 3 ).
Healthcare resource utilization
Severe hypoglycaemic event-related resource utilization Ninety-nine of 140 episodes of severe hypoglycaemia (71%) involved ambulance call-outs (Table 2) , of which 83 required ª 2018 Diabetes UK no onward emergency care. Sixteen call-outs led to A&E attendance, of which five led to non-elective inpatient admission. Ten episodes (7%) involved A&E visits without ambulance call-out or admission, two (1%) episodes involved other hospital interventions and 29 (21%) episodes were managed without immediate healthcare professional (HCP) intervention ( Table 2 ). The mean cost of the early management of severe hypoglycaemia during the 2-year observation period was £240.52 per episode (Table 2) . Ambulance call-out costs alone (£18 668) accounted for 55.4% of the total severe hypoglycaemia-related healthcare expenditure.
Diabetes clinic consultations during the 2-year observation period
During the 2-year observation period, participants attended a median of 5 (IQR 2-7; range 0-58) diabetes clinic consultations (Table 3) . Only 70 of 552 (13%) consultations were recorded as for hypoglycaemia follow-up (in 48 people); of these, 10 of 70 (14%) did not follow a reported episode. The median time between episodes of severe hypoglycaemia and hypoglycaemia follow-up consultations (n = 60) was 2 (range 0-270) days, with 19 of 60 (32%) taking place on the same day (telephone consultations) (Fig. 2) .
Adjustments to diabetes treatment
Overall, 119 HCP-recommended adjustments to diabetes treatment were recorded during the 2-year observation period (median per person 0, range 0-11). The most commonly recorded reason for treatment changes was hypoglycaemic event (52 of 119 changes, 44%) ( Table 4) .
Timing of diabetes clinic visits and anti-diabetes medication adjustments in relation to severe hypoglycaemia For the subgroup of 72 episodes of severe hypoglycaemia with 3 months' data available pre-and post-hypoglycaemia, 68 routine diabetes management and 41 hypoglycaemia follow-up consultations were recorded during the 6-month period; of these, 28 of 109 (26%) occurred during the 3 months before, 12 of 109 (11%) occurred on the same day (telephone consultations) and 69 of 109 (63%) occurred during the 3 months after the event. Forty diabetes treatment changes were recorded during this 6-month period; of these, 7 of 40 (18%) occurred during the 3-months before (median 0, range 0-3; 4 of 7 changes were dose increases), 4 of 40 (10%) occurred on the same day (median per person 0, range 0-2) and 29 of 40 (73%) occurred during the 3 months after the episodes of severe hypoglycaemia. Forty-three per cent of changes were dose reductions, all of which were recorded in the 3 months following episodes of severe hypoglycaemia.
Non-hypoglycaemia-related NHS resource utilization
Overall, 118 non-hypoglycaemia-related hospital attendances/admissions were recorded during the 2-year observation period, including 45 non-elective admissions (Fig. S1 ).
Discussion
Despite the association between intensive/tight glycaemic control and the increased risk of hypoglycaemia reported in the DCCT [1, 4] , the large majority of participants with selfreported severe hypoglycaemia in our study had relatively poor glycaemic control. Two-fifths of participants had more than one episode of severe hypoglycaemia during the 2-year observation period and almost three-quarters of all episodes involved an ambulance call-out. Despite this, the frequency of diabetes clinic consultations and HbA 1c assessments was lower than expected. Only 13% of consultations were documented as being for hypoglycaemia follow-up and at least 50% of participants did not have any HCP-recommended changes to diabetes treatment documented during the 2-year observation period.
The frequency of severe hypoglycaemia observed in our study is consistent with the prevalence estimated in people with Type 1 diabetes from real-world studies of between 0.7 [16] . We also found that 71% of all hypoglycaemic episodes involved ambulance callouts, which is greater than that reported in clinical trials [17] . This may reflect the practice of excluding people with Type 1 diabetes at high risk of severe hypoglycaemia from clinical trials, and differences in age and social support between our study population and clinical trial participants.
The majority of people in our study were treated with MDI insulin analogues, consistent with National Institute for Health and Care Excellence (NICE) recommendations for adults with Type 1 diabetes [8] . However, only 11% achieved an HbA 1c at or below the NICE recommended target of 48 mmol/mol (6.5%) at any point during the observation period. These data are consistent with previous studies including DCCT [1] , the National Diabetes Audit (NDA) [18] and results of a recent systematic review and meta-analysis [19] , and suggest that the current NICErecommended HbA 1c target remains aspirational and unachievable for the majority of people. The relatively poor glycaemic control observed in our study is consistent with previous studies demonstrating that severe hypoglycaemia is associated with greater glucose variability and higher HbA 1c levels [20, 21] . Severe hypoglycaemia is also associated with longer duration of diabetes, impaired hypoglycaemia awareness, cognitive impairment, increased burden of comorbidities, b-blocker use and alcohol use [20] [21] [22] , suggesting the high burden of comorbidities and concomitant medication use observed in our study may have contributed to the increased risk for developing severe hypoglycaemia. The ambulance service managed the majority of severe hypoglycaemic episodes without a requirement for A&E or inpatient admission, consistent with results of previous realworld studies [11] [12] [13] [14] 23, 24] . This is likely to reflect UK recommendations for the development of pathways of care to reduce inpatient admissions in people with diabetes, including 'see and treat' policies for managing severe hypoglycaemia without admission, where appropriate [10] . Importantly, it is also recommended that collaborative pathways of care link hypoglycaemia-related ambulance attendances with enhanced diabetes education and medication review by patients' usual diabetes service [10] . Therefore, considering NICE recommends review and HbA 1c measurements every 3-6 months for people with uncomplicated Type 1 diabetes [8] , the frequency of outpatient review for this high-risk cohort was low. Although two-fifths of participants had more than one episode of severe hypoglycaemia, only 13% of all diabetes clinic visits were recorded as being for hypoglycaemia follow-up. Despite a higher frequency of diabetes clinic consultations for routine diabetes management or hypoglycaemia follow-up in the 3 months after an episode than before, there is no indication in our study of a sustained increase in frequency of review following severe hypoglycaemia. Furthermore, no changes to diabetes treatment were recorded in > 50% of our participants during the 2-year observation period. Therefore, despite considerable innovation in the development of effective pathways for automatic ambulance service referral of people with hypoglycaemia to primary, community and secondary care services for early follow-up [12, 14, 25] , our results may suggest that specialist diabetes services are clinically unresponsive to (or remain unaware of) severe hypoglycaemic episodes. However, because individuals routinely self-manage their insulin therapy to balance daily carbohydrate consumption and activity, it is possible that some participants were aware of the cause of hypoglycaemia and took action to avoid future occurrences without requiring healthcare advice.
The rates of admissions for severe hypoglycaemia in individuals with Type 1 diabetes, after adjusting for population prevalence, has fallen in recent years; however, due to the increasing prevalence of diabetes, treatment of severe hypoglycaemia has important implications for healthcare resources [26] . Admissions for severe hypoglycaemia have been estimated to cost the National Health Service (NHS) an average of £1034 per event [27] . Our study has estimated that the average cost associated with self-reported episodes of severe hypoglycaemia that are largely managed without hospital admission is £240.52, with the major financial burden being shouldered by the ambulance service. These results are broadly consistent with previous UK studies specifically evaluating severe hypoglycaemia requiring ambulance service attendance [11, 14, 24] . However, the burden of severe hypoglycaemia is not only financial: there is also a significant effect on individuals in terms of reduced quality of life, reduced work productivity and poorer clinical outcomes [16] . Most importantly, it has been reported that 4.45% of people with Type 1 diabetes with severe hypoglycaemia requiring an ambulance call-out died within 12 months of the last presentation, with a median age of 54 years [13] , and 5.2% of people hospitalized for severe hypoglycaemia died within 30 days in 2010 [28] . In this context, the high level of ambulance service intervention but low levels of hypoglycaemia follow-up, therapy change and specialist intervention observed in our study suggests; a missed opportunity fi∞AErst, a missed opportunity to reduce future risk of hypoglycaemia; and a need for greater integration of care pathways for people with Type 1 diabetes and severe hypoglycaemia. The majority of episodes of severe hypoglycaemia evaluated in our study required ambulance service attendance, supporting the prominent role of ambulance services in delivering, or facilitating access to, healthcare advice and support at a time when people (and carers) may be most receptive [11, 12, 14, 23, 24] . However, 21% of episodes in our study did not involve immediate HCP intervention, suggesting that directly questioning people with Type 1 diabetes about episodes of severe hypoglycaemia using standardized clinical scales at every diabetes clinic visit may help to improve reporting, evaluation and intervention for all people experiencing severe hypoglycaemia. Strengths and weaknesses of the study Our cohort may not be representative of the wider population of people with Type 1 diabetes suffering severe hypoglycaemia for a number of reasons. The majority of people included in this study were older than 55 years, broadly consistent with previous observational studies [13, 14, 24] and suggesting that older people with Type 1 diabetes are more prone to episodes of severe hypoglycaemia [29] . However, younger people with Type 1 diabetes (< 40 years) are reported to be less likely to attend diabetes appointments [18] and are less likely to self-report severe hypoglycaemia due to the risk of disqualification from driving [30] . Therefore, younger people may be underrepresented in our cohort and those of previous observational studies. As with all retrospective studies, the interpretation of our results is reliant on the quality of the information available in participants' medical records. Therefore, as participant identification relied on self-reported severe hypoglycaemia, those episodes requiring no interaction with NHS services could not be verified and are likely to have been under-reported (because of unwillingness or recall bias), leading to an overestimation of the proportion of episodes requiring ambulance call-out. We also cannot exclude the possibility that HCP recall bias influenced participant identification and selection, although a variety of methods were employed to identify eligible individuals. Furthermore, the limited number of consultations for hypoglycaemia follow-up may reflect a lack of detailed recording of discussions about hypoglycaemia during consultations, especially in instances where the cause was known and considered unlikely to recur. The study included people reporting severe hypoglycaemia at any point within the previous 2 years; therefore, people had a variable period of follow-up before and after the event which may have limited the time available to observe changes in diabetes management. Furthermore, since many patient pathways for linking hypoglycaemia-related ambulance attendances with diabetes services have been implemented since 2014, it is possible that people requiring ambulance attendance earlier during the study observation period may have been less likely to have been referred to diabetes services than those towards the end of the observation period. One strength of this study is that participants were recruited from 10 hospitals distributed geographically across England and Wales, so the results may be generalizable to the UK population. In addition, we evaluated emergency and non-emergency hospital resource utilization, including all diabetes centre consultations, HbA 1c evaluations and HCPrecommended changes to diabetes therapy. This has enabled an evaluation of the temporal relationship between severe hypoglycaemia and secondary care interventions. However, we were not able to evaluate costs associated with posthypoglycaemia consultations in primary care; this is worthy of further study.
Conclusions
The results of our study suggest three gaps in the diabetes care pathway warranting further evaluation: (1) lack of a consistent mechanism for reporting by paramedics to primary care and subsequent referral of individuals to specialist diabetes services, (2) lack of a consistent approach to early follow-up of self-reported episodes of severe hypoglycaemia by specialist diabetes services, and (3) low levels of HCPrecommended therapy change and ongoing specialist review following self-reported episodes of severe hypoglycaemia.
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